Brief: Acer Therapeutics Announces Topline Results From ACER-801 Phase 2a Trial

Acer Therapeutics

17/03/2023 13:22

March 17 (Reuters) - Acer Therapeutics Inc  ACER.O :
    * ACER THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM ACER-801
(OSANETANT) PHASE 2A TRIAL
    * ACER THERAPEUTICS INC - ACER-801 WAS SAFE AND
WELL-TOLERATED BUT
DID NOT ACHIEVE STATISTICAL SIGNIFICANCE
    * ACER THERAPEUTICS INC - PAUSING ACER-801 PROGRAM UNTIL
ACER HAS
CONDUCTED A THOROUGH REVIEW OF FULL DATA SET
    * ACER THERAPEUTICS INC - CONTINUING TO FOCUS ON PREPARATION
FOR
ITS COMMERCIAL LAUNCH OF OLPRUVA
    * ACER THERAPEUTICS - EXISTING CASH & CASH EQUIVALENTS WILL
BE
SUFFICIENT TO FUND ANTICIPATED OPERATING, CAPITAL REQUIREMENTS
INTO EARLY IN Q2
    * ACER THERAPEUTICS INC - WILL REQUIRE ADDITIONAL FINANCING
TO
COMMERCIALIZE OLPRUVA

Source text for Eikon:  ID:nGNXGLgp9 
Further company coverage:  ACER.O 

 ((Reuters.Briefs@thomsonreuters.com;))